2022
DOI: 10.22159/ijap.2022v14i1.42764
|View full text |Cite
|
Sign up to set email alerts
|

Formulation and Development of Fixed-Dose Combination of Bi-Layer Tablets of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets 600 Mg/300 Mg/300 Mg

Abstract: Objective: This study is to formulate bi-layer tablet as a multidrug regimen against each reference listed drugs of Brand SUSTIVA® (efavirenz tablets 600 mg), EPIVER®(lamivudine tablets 300 mg), and VIREAD®(tenofovir disoproxil tablets 300 mg) to treat human immunodeficiency virus (HIV) infections. Which provides highly active antiretroviral therapy to provide effective treatment. Methods: Bilayer formulation was developed with each blend of layer-I (efavirenz) and layer-II (lamivudine and tenofovir disoproxil… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…XRD data for the test formulation was compared to that of the reference listed drug, confirming that no polymorphic alterations had occurred in the drug product and ensuring that the developed formulation was more stable and resilient [33,34].…”
Section: Polymorphic Studymentioning
confidence: 84%
See 1 more Smart Citation
“…XRD data for the test formulation was compared to that of the reference listed drug, confirming that no polymorphic alterations had occurred in the drug product and ensuring that the developed formulation was more stable and resilient [33,34].…”
Section: Polymorphic Studymentioning
confidence: 84%
“…These formulation variables helped to identify the critical material attributes (CMAs) and critical process parameters (CPPs). Which research was required to produce a steady, reliable product [23][24][25][26][27][28][29][30][31][32][33].…”
Section: Formulation Developmentmentioning
confidence: 99%